ArticleJournal of personalized medicine2022
Effectiveness of Platelet-Rich Plasma Therapy in Androgenic Alopecia-A Meta-Analysis.
Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Comparative Efficacy and Safety of Platelet Rich Plasma (PRP) versus Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis.Aesthetic plastic surgery · 2026Pooled it
- Evaluation of the effects of adding an adipose tissue-derived stromal vascular fraction to platelet-rich plasma injection in the treatment of androgenetic alopecia: A randomized clinical trial.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Trial
- Microneedle technology integrated with diverse therapeutic modalities for hair regrowth in alopecia.Acta pharmaceutica Sinica. B · 2026Review
- Androgenetic alopecia in polycystic ovary syndrome: a cutaneous marker of systemic metabo-inflammatory and endocrine dysfunction.Endocrine connections · 2026Review
- Comparison of the efficacy of platelet-rich plasma with topical minoxidil in treating patients with androgenetic alopecia: a systematic review of clinical trials.Skin health and disease · 2025Review
- Effectiveness of Autologous Platelet-Rich Plasma for Androgenetic Alopecia: A Double-Center, Non-Controlled, Randomized Clinical Study in Vietnam.Clinical, cosmetic and investigational dermatology · 2025Article
- Review
- Intracavernous injection of platelet-rich plasma reverses erectile dysfunction of chronic cavernous nerve degeneration through reduction of prostate hyperplasia evidence from an aging-induced erectile dysfunction rat model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Personalized Medicine in the Field of Inflammatory Skin Disorders.Journal of personalized medicine · 2022Article
- Female-pattern hair loss: therapeutic update.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich plasma (PRP) represents a novel therapy tested and is used more and more frequently in dermatology and cosmetic surgery for a variety of conditions, including androgenic alopecia (AGA), a common condition with a complex pathogenesis involving genetic factors, hormonal status and inflammation. We performed an extensive literature search which retrieved 15 clinical trials concerning the use in AGA of PRP therapy, alone or in combination, in male, female or mixed patient groups. A quantitative statistical meta-analysis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.